(Q40260056)

19 September 2017

title

A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). (English)

1 reference

19 September 2017

Friedman MA

1

1 reference

19 September 2017

Ignoffo RJ

series ordinal

2

1 reference

19 September 2017

publication date

1 December 1980

1 reference

19 September 2017

published in

Cancer Treatment Reviews

1 reference

19 September 2017

volume

7

1 reference

19 September 2017

issue

4

1 reference

19 September 2017

page(s)

205-213

1 reference

Results of treatment of malignant tumors with ftorafur

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

Ftorafur, adriamycin, cyclophosphamide and bcg in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

5-fluorouracil, adriamycin, and mitomycin-c (fam) combination chemotherapy in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

Phase I study of ftorafur, an analog of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

A phase II trial of ftorafur. Adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2880%2980037-5

7 January 2021

10.1016/S0305-7372(80)80037-5

Identifiers

DOI

1 reference

19 September 2017

1 reference